Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Inotodiol inhibits HCC cell viability.

(A)The influence of inotodiol on the survival of HCC cells and liver cells was examined over a 48-hour timeframe using the CCK-8 assay with a range of concentrations, n = 3. (B)The influence of inotodiol on the survival of HCC cells and liver cells was examined over a 72-hour timeframe using the CCK-8 assay with a range of concentrations, n = 3.

More »

Fig 1 Expand

Fig 2.

Inotodiol inhibits sk-hep-1, hepG2 cells migration.

(A-B)Effect of inotodiol treatment of sk-hep-1 cells on the healing area of scratches and statistical results. (C-D)Effect of inotodiol treatment of hepG2 cells on the healing area of scratches and statistical results. *significantly different from control group. *p<0.05, **p<0.01, n = 3.

More »

Fig 2 Expand

Fig 3.

Inotodiol decreases clone formation in HCC cells.

(A-B) The Clone formation assay and the number of clones. *significantly different from control group. ***p<0.001, ****p<0.0001, n = 3.

More »

Fig 3 Expand

Fig 4.

Inotodiol-mediated cell cycle halt at the G1 phase in HCC cells.

(A-D) Inotodiol elevated the prevalence of cells within the G1 phase of the cell cycle. (E-F) Western blotting assay for the analysis of CDK2, CDK4, CDK6, cyclin D expression in inotodiol-treated sk-hep-1 cells at indicated concentration for 48h. (G-H) Western blotting assay for the analysis of CDK2, CDK4, CDK6, cyclin D expression in inotodiol-treated hepG2 cells at indicated concentration for 48h. *significantly different from control group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n = 3.

More »

Fig 4 Expand

Fig 5.

Inotodiol triggered apoptosis in HCC cells.

(A-B) The apoptosis rate of inotodiol-treated sk-hep-1 and hepG2 cells after 48 hours was detected using flow cytometry. (C-F) Examination of the expression profiles of proteins associated with apoptosis in the sk-hep-1 (C-D) and hepG2 (E-F) cell lines was conducted using western blotting after the treatment with inotodiol.*significantly different from control group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n = 3.

More »

Fig 5 Expand

Fig 6.

Inotodiol inhibits MAPK/ERK pathways in HCC cells.

(A-E) Protein expression and statistical results of RAS/RAF/MEK/ERK pathway related proteins in sk-hep-1 cells ascertained by Western Blot. (F-J) Protein expression and statistical results of MAPK/ERK pathway related proteins in hepG2 cells detected by Western Blot. NS, not significant different from control group, *significantly different from control group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n = 3.

More »

Fig 6 Expand

Fig 7.

Inotodiol inhibits the growth of liver cancer tumors in mice.

(A-B) Photos of subcutaneous tumors in mice from each group. *significantly different from control group. *p<0.05, ***p<0.001, ****p<0.0001, n = 3.

More »

Fig 7 Expand

Table 1.

The effect of inotodiol on the tumor volume and weight in tumor-bearing mice.

More »

Table 1 Expand

Table 2.

The effect of inotodiol on the body weight and organ mass of tumor-bearing mice.

More »

Table 2 Expand